Alnylam Pharmaceuticals ALNY Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's deferred revenue?
- Alnylam Pharmaceuticals (ALNY) reported deferred revenue of $4.01M in Q2 2026.
- How has Alnylam Pharmaceuticals's deferred revenue changed year-over-year?
- Alnylam Pharmaceuticals's deferred revenue decreased by 73.4% year-over-year, from $15.08M to $4.01M.
- What is the long-term trend for Alnylam Pharmaceuticals's deferred revenue?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's deferred revenue has grown at a -48.0% compound annual growth rate (CAGR), from $127.21M to $4.85M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.